YIH
KZR

Y-Intercept (HK)’s Kezar Life Sciences KZR Stock Holding History

Y-Intercept (HK)’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22,770
Closed -$137K – 1576
2024
Q2 		$137K Buy
+22,770
New +$173K 0.01% 1226
2023
Q3 		– Sell
-1,960
Closed -$48K – 1349
2023
Q2 		$48K Sell
1,960
-1,652
-46% -$43K 0.01% 1200
2023
Q1 		$113K Buy
+3,612
New +$209K 0.01% 1041

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Y-Intercept (HK)'s KZR Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Kezar Life Sciences (KZR) in Q3 2024, closing a stake of 22,770 shares — an estimated $137K sold.

Y-Intercept (HK) first reported a position in KZR in Q1 2023 and held it in 3 quarters. The position peaked at $137K in Q2 2024. 59 funds tracked by Wall St. Rank hold KZR as of Q3 2024.

  • Y-Intercept (HK) reported no remaining Kezar Life Sciences position as of Q3 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 22,770 Kezar Life Sciences shares in Q3 2024, an estimated $137K.
  • Y-Intercept (HK) first reported a position in Kezar Life Sciences in Q1 2023 and held it in 3 quarters.
  • Y-Intercept (HK)'s Kezar Life Sciences position peaked at $137K in Q2 2024.
  • 59 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.